PT  - JOURNAL ARTICLE
AU  - MAESTRO, LUISA M.
AU  - SASTRE, JAVIER
AU  - RAFAEL, SARA B.
AU  - VEGANZONES, SILVIA B.
AU  - VIDAURRETA, MARTA
AU  - MARTÍN, MIGUEL
AU  - OLIVIER, CARLOS
AU  - DE LA ORDEN, VIRGINIA B.
AU  - GARCIA-SAENZ, JOSE ANGEL
AU  - ALFONSO, ROSARIO
AU  - ARROYO, MANUEL
AU  - DIAZ-RUBIO, EDUARDO
TI  - Circulating Tumor Cells in Solid Tumor in Metastatic and Localized Stages
DP  - 2009 Nov 01
TA  - Anticancer Research
PG  - 4839--4843
VI  - 29
IP  - 11
4099  - http://ar.iiarjournals.org/content/29/11/4839.short
4100  - http://ar.iiarjournals.org/content/29/11/4839.full
SO  - Anticancer Res2009 Nov 01; 29
AB  - The aim of this study was the detection of circulating tumor cells (CTC) in three tumor types of epithelial origin. Patients and Methods: Four hundred and thirty-eight patients with breast cancer (56.2% localized and 43.8% metastatic), 195 with colorectal tumors (84.1% localized and 15.9% metastatic) and 50 with prostate cancer (52% localized and 48% metastatic) took part in this study. CTC quantification was performed using the CellSpotter Analyzer (Veridex® LLC). Results: 31.5% of patients with cancer had ≥2 CTCs/7.5 mL but none of the healthy volunteers were above this level (p<0.001). Among patients with metastatic disease, 62.3% of them had ≥2 CTCs/7.5 mL but only 14.0% of those with localized disease were above this level (p<0.001). The presence of CTCs were correlated to stage in the three studied tumor types and no differences in the number of cells were found between them. Conclusion: The presence of more than 2 CTCs/7.5 ml is a frequent event in metastatic cases. In particular, patients with localized disease who have more than 2 CTCs/7.5 ml should be carefully studied to determine the possible prognostic and predictive value of this finding.